Arcus Biosciences, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$1.14B
↓-1.0% -$11Mvs FY2024
Total Liabilities
$231M
↑+2.2% +$5Mvs FY2024
Equity
$631M
↑+30.1% +$146Mvs FY2024
Cash
$222M
↑+48.0% +$72Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.14B | $1.15B |
| Current Assets | $1.01B | $1.02B |
| Cash | $222M | $150M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $785M | $866M |
| Non-Current Assets | $132M | $134M |
| PPE | $40M | $47M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $92M | $87M |
| Total Liab+Eq | $631M | $485M |
| Current Liab. | $231M | $226M |
| Accounts Payable | $42M | $18M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $35M | $85M |
| Other CL | $154M | $123M |
| Non-Current Liab. | $0 | $0 |
| Long-Term Debt | $99M | $48M |
| Other LT Liab. | $0 | $0 |
| Equity | $631M | $485M |
| Retained Earnings | $1.49B | $1.13B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · RCUS · Comparing FY2025 vs FY2024